Data from haemodynamic early phase clinical trials of GLP-1/glucagon dual agonists demonstrates Cotadutide (MEDI0382)16,17,98, Survodutide (BI 456906)19,99 and Mazdutide (IBI362)100 increase heart rate and reduce blood pressure in patients with T2D or obesity. Here, GCG is linked to Obesity.